Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ironwood Pharma ( (IRWD) ) just unveiled an update.
On January 17, 2025, Ironwood Pharmaceuticals announced a significant workforce reduction of approximately 50% to streamline operations and focus on its strategic pipeline, affecting mainly field-based sales employees. This move is expected to result in charges of $20.0 to $25.0 million, with most costs incurred in the first half of 2025. Additionally, on January 29, 2025, Gregory Martini was promoted to Senior Vice President, Chief Financial Officer, effective January 27, 2025, succeeding Thomas McCourt in this role.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company’s primary market focus is on gastrointestinal therapies, aiming to address unmet medical needs in this field.
YTD Price Performance: -12.24%
Average Trading Volume: 1,970,983
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $608.1M
For detailed information about IRWD stock, go to TipRanks’ Stock Analysis page.
